Critical appraisal of the use of regorafenib in the management of colorectal cancer

References

• FerlayJShinH-RBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer20081272893291721351269
   PubMed Web of Science ®Google Scholar
• SegalNHSaltzLBEvolving treatment of advanced colon cancerAnnu Rev Med20096020721919630571
   PubMed Web of Science ®Google Scholar
• CohenSJCohenRBMeropolNJTargeting signal transduction pathways in colorectal cancer – more than skin deepJ Clin Oncol2005235374538515998904
   PubMed Web of Science ®Google Scholar
• CunninghamDHumbletYSienaSCetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med200435133734515269313
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med20043502335234215175435
   PubMed Web of Science ®Google Scholar
• Van CutsemEPeetersMSienaSOpen-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancerJ Clin Oncol200725131658166417470858
   PubMed Web of Science ®Google Scholar
• DaviesHBignellGRCoxCMutations of the BRAF gene in human cancerNature2002417689294995412068308
   PubMed Web of Science ®Google Scholar
• AndreyevHJNNormanARCunninghamDKirsten ras mutations in patients with colorectal cancer: the “RASCAL II” studyBr J Cancer200185569269611531254
   PubMed Web of Science ®Google Scholar
• TakahashiYKitadaiYBucanaCDExpression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancerCancer Res199555396439687664263
   PubMed Web of Science ®Google Scholar
• CarmelietPJainRKAngiogenesis in cancer and other diseasesNature200040724925711001068
   PubMed Web of Science ®Google Scholar
• FerraraNVEGF and the quest for tumor angiogenesis factorNat Rev Cancer200221079580312360282
   PubMed Web of Science ®Google Scholar
• EllisLMHicklinDJVEGF-targeted therapy: mechanisms of anti-tumor activityNat Rev Cancer2008857959118596824
   PubMed Web of Science ®Google Scholar
• FongGHRossantJGertsensteinMBreitmanMLRole of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endotheliumNature199537666707596436
   PubMed Web of Science ®Google Scholar
• ShalabyFRossantJYamaguchiTPFailure of blood-island formation and vasculogenesis in Flk-1-defcient miceNature199537662667596435
   PubMed Web of Science ®Google Scholar
• AcevedoVDIttmannMSpencerDMPaths of FGFR-driven tumorigenesisCell Cycle2009858058819182515
   PubMed Web of Science ®Google Scholar
• BergersGSongSMeyer-MorseNBergslandEHanahanDbenefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsJ Clin Invest20031111287129512727920
   PubMed Web of Science ®Google Scholar
• BachFUddinFJBurkeDAngiopoietins in malignancyEur J Surg Oncol20073371516962282
   PubMed Web of Science ®Google Scholar
• SaitoMWatanabeJFujisawaTAngiopoietin-1, 2 and Tie2 expressions in endometrial adenocarcinoma – the Ang2 dominant balance up-regulates tumor angiogenesis in the presence of VEGFEur J Gynaecol Oncol20062712913416620053
   PubMed Web of Science ®Google Scholar
• SzarvasTJagerTTotschMAngiogenic switch of angiopoietins– Tie2 system and its prognostic value in bladder cancerClin Cancer Res2008148253826219088043
   PubMed Web of Science ®Google Scholar
• LanziCCassinelliGNicoliniVZuninoFTargeting RET for thyroid cancer therapyBiochem Pharmacol20097729730919028457
   PubMed Web of Science ®Google Scholar
• NikiforovYEThyroid carcinoma:molecular pathways and therapeutic targetsMod Pathol200821Suppl 23743
   PubMed Web of Science ®Google Scholar
• FletcherJARubinBPKIT mutations in GISTCurr Opin Genet Dev2007173717208434
   PubMed Web of Science ®Google Scholar
• HeinrichMCBlankeCDDruckerBJCorlessCLInhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignanciesJ Clin Oncol20022061692170311896121
   PubMed Web of Science ®Google Scholar
• BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer2008859260318650835
   PubMed Web of Science ®Google Scholar
• Van CutsemETaberneroJLakomyRIntravenous aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262-VELOUR)Ann Oncol20112222
   Web of Science ®Google Scholar
• HechtJRTrarbachTJaegerEA randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic a line chemotherapy with oxaliplatin/5-fuorouracil/leucovorin and PTK787/ ZK222584 or placebo (CONFIRM-1)J Clin Oncol2005Suppl 23 Abstract 3
   Google Scholar
• MrossKBuchertMFasolUA preliminary report of a phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment – a study of the CESAR Central European Society for Anticancer Drug Research – EWIVInt J Clin Pharmacol Ther20111969821176744
   PubMed Web of Science ®Google Scholar
• SiuLLShapiroJJonkerJPhase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wildtype (WT) colorectal carcinoma (CRC): the NCIC Clinical Trials Group and AGITG CO.20 trialJ Clin Oncol201230Suppl 4386
   Web of Science ®Google Scholar
• ScottMWilhelmSMDumasJRegorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInt J Cancer201112924525521170960
   PubMed Web of Science ®Google Scholar
• MrossKFrostASteinbildSHedbomSA phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumorsClin Cancer Res20121892658266722421192
   PubMed Web of Science ®Google Scholar
• StrumbergDScheulenMESchultheisBRegorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I studyBr J Cancer2012106111722177722568966
   PubMed Web of Science ®Google Scholar
• GrotheyAVan CutsemESobreroARegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet20133819863303312
   PubMed Web of Science ®Google Scholar
• WaddellTCunninghamDEvaluation of regorafenib in colorectal cancer and GISTLancet Oncol20133819863273275
   Web of Science ®Google Scholar